Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma (NCT03465592)
Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.
Who can join: Review the eligibility criteria below.
Location: Johns Hopkins All Children's Hospital — St. Petersburg, Florida
Age range: 12 Months to 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
- Johns Hopkins Hospital — Baltimore, Maryland
- Albert Einstein College of Medicine, Children's Hospital at Montefiore — The Bronx, New York
- New York Medical Center/ Maria Fareri Children's Hospital — Valhalla, New York
📞 Contact the Study Coordinator
Phone: (410) 955-0432
Email: mpetryc1@jhmi.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sarcoma
- Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study — Durham, North Carolina
- Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma — Milwaukee, Wisconsin
- Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor — New York, New York
- Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma — Houston, Texas
- Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® — Philadelphia, Pennsylvania
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma — New York, New York
Explore by condition: All Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.